This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sun, L. Articles by Fan, L. Search for Related Content PubMed PubMed Citation Articles by Sun, L. Articles by Fan, L. Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                   What's this?

Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus

HY Zhang

XB Feng

Department of Rheumatology and Immunology, Drum Tower Clinical College of Nanjing Medical University, China

YY Hou

Immunology Lab, Nanjing University Medical School, China

LW Lu

Department of Pathology, University of HongKong Nanjing Medical University, China

LM Fan

Department of Pathophysiology, Nanjing Medical University, China; Department of Pathophysiology, Nanjing Medical University, Nanjing, 210029, P.R. China lmfan{at}njmu.edu.cn

Bone marrow-derived mesenchymal stem cells (MSCs) are key components of the hematopoietic microenvironment and provide support to hematopoiesis and modulate immune system. Several studies suggest that SLE may be seen as stem cell disorders. However, it is unclear that whether MSCs from SLE patients are defective. So in this research, we studied the biological character of bone marrow derived MSCs in patients with SLE, focused on their phenotype (morphology and immunophenotype), karyotype, cytokines expression and hematopoietic support of MSCs. Our results showed that MSCs from SLE patients and normal controls can be successfully culture-expanded, but the MSCs from SLE grew more slowly than those of normal controls (P < 0.05). Cells from both groups were positive for CD29, CD44 and CD105, and negative for CD14, CD34, CD45 and HLADR. MSCs from SLE have a normal karyotype. Both groups express IL-6, IL7, IL-11, macrophage colony stimulating factor (M-CSF) and stem cell factor (SCF) at mRNA level. While IL-6 and IL-7 were down-regulated in MSCs from SLE patient (P < 0.05) at mRNA level. The MSCs from SLE patients and normal controls were infused into ICR (Tac: Icr: Ha strain) mice after high-dose chemotherapy, with no adverse events in either group. Recovery of white blood cells, hemoglobin and platelet was more rapid (P < 0.05) compared with the group without MSCs infusion. We conclude that MSCs in patient with SLE have abnormalities compared with those in normal control. MSCs in patient with SLE may play an important role in the SLE pathogenesis.

Key Words: biological character • cytokine • hematopoietic support • mesenchymal stem cells • systemic lupus erythematosus

Lupus, Vol. 16, No. 2, 121-128 (2007)
DOI: 10.1177/0961203306075793


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Sun, K. Akiyama, H. Zhang, T. Yamaza, Y. Hou, S. Zhao, T. Xu, A. Le, and S. Shi Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and Humans Stem Cells, June 1, 2009; 27(6): 1421 - 1432. [Abstract] [Full Text] [PDF]

				T Fukushima, L Dong, T Sakai, T Sawaki, M Miki, M Tanaka, Y Masaki, Y Hirose, M Kuwana, and H Umehara Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus Lupus, March 1, 2008; 17(3): 210 - 214. [Abstract] [PDF]

				K. C. Tang, K. A. Trzaska, S. V. Smirnov, S. V. Kotenko, S. K. Schwander, J. J. Ellner, and P. Rameshwar Down-Regulation of MHC II in Mesenchymal Stem Cells at High IFN-{gamma} Can Be Partly Explained by Cytoplasmic Retention of CIITA J. Immunol., February 1, 2008; 180(3): 1826 - 1833. [Abstract] [Full Text] [PDF]